INmune Bio Inc logo

INmune Bio Inc

$ 8.35 +0.09 (+1.09%) 10:08 PM EST
P/E:
At Loss
P/B:
2.35
Market Cap:
$ 149.85M
Enterprise V:
$ 107.82M
Volume:
51.17K
Avg Vol (2M):
60.32K
Volume:
51.17K
Market Cap $:
149.85M
PE Ratio:
At Loss
Avg Vol (2-Month):
60.32K
Enterprise Value $:
107.82M
PB Ratio:
2.35

Business Description

Description
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow the immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
Name Current Vs Industry Vs History
Cash-To-Debt 3.73
Equity-to-Asset 0.76
Debt-to-Equity 0.24
Debt-to-EBITDA -0.52
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.69
Distress
Grey
Safe
Beneish M-Score 9.33
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 65.82
9-Day RSI 61.86
14-Day RSI 59.76
6-1 Month Momentum % -26.57
12-1 Month Momentum % -18.43

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 9.67
Quick Ratio 9.67
Cash Ratio 8.33

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -16.7